Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J)
Hypertension, Coronary Atherosclerosis
About this trial
This is an interventional prevention trial for Hypertension focused on measuring Hypertension, PCI, Calcium Channel Blockers, IVUS, Plaque
Eligibility Criteria
Inclusion Criteria: Age: Between 20 and 79 years (at the time of giving informed consent). Sex: Either sex. Admission status: Outpatients. Patients requiring treatment for hypertension according to the JSH 2004 hypertension therapy guidelines before beginning this study Patients who have not used any calcium antagonists for at least 4 weeks before the beginning of this study. Patients who are scheduled to undergo elective PCI. Exclusion Criteria: Patients with acute coronary syndrome (ACS). Patients who have experienced Q-wave myocardial infarction within 4 weeks before beginning this study. Patients with renal dysfunction (serum creatinine >2.0 mg/dL). Patients in whom PCI is unsuccessful. Patients with cardiogenic shock. Patients with moderate or severe congestive heart failure. Patients with 50% or more stenosis of the main trunk of the left coronary artery. Patients with other problems whom the investigator considers unsuitable for this study.
Sites / Locations
- Department of Cardiology, Juntendo University School of Medicine
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
1
2
Amlodipine
Azelnidipine